Long-term graft function of cryostored alginate encapsulated rat islets by Schneider, Stephan & Klein, Harald H
396 september 12, 2011 Eu  Ro  PE  an JouR  naL of MEd  I  caL RE  sEaRcH
Abstract
Microencapsulation of pancreatic islets before trans-
plantation  is  a  promising  approach  to  enable  graft
function  in  an  immunocompetent  recipient  without
immunosuppression.  However,  the  insufficient  avail-
ability of allogenic islet tissue is a major problem. one
concept to overcome these shortcomings is the cryop-
reservation of encapsulated allogenic islets. Recently,
we reported a gentle cryopreservation protocol for rat
islets encapsulated in an alginate-based microcapsule
system. Here, we report for the first time long-term
transplantation data of these cryopreserved microen-
capsulated islets. We detected a stable graft function
for more than 12 month (experiments still continuing)
after transplantation of 2500 cryopreserved microen-
capsulated  cd  rat  islets  in  streptozotocin-diabetic
Wistar rats. Moreover, the glucose clearance rate dur-
ing an IPgtt was well preserved up to 56 weeks after
transplantation. In addition, hyperglycemic blood glu-
cose levels after removal of rat islet grafts 12 and 56
weeks after transplantation confirmed the efficacy of
the encapsulated islets. finally, the retrieved encapsu-
lated rat islets responded well with a 7-fold increase of
insulin  secretion  to  a  glucose  stimulus  (12  and  56
weeks). In conclusion, our study demonstrates for the
first  time  that  cryopreservation  of  encapsulated  rat
islets  is  possible  without  substantial  losses  on  graft
function for a very long time. 
Key words: rat islets, alginate capsules, transplantation,
cryopreservation, insulin secretion
IntRoductIon
Islet  transplantation  is  one  concept  to  cure  patients
with type 1 diabetes [1, 2]. However, one drawback of
islet transplantation is that this technique requires the
administration of immunoﾬsupﾬpressiva that may be
associated with serious side effects, e.g. loss of kidney
function  [2].  Moreover,  these  drugs  directly  impair
beta-cell function and reduce the regenerative capacity
of islet tissue [3]. We and others have shown that a
bioartificial pancreas consisting of islets immunopro-
tected  by  an  alginate  microcapsule  provides  a  very
promising approach to overcome the rejection prob-
lem  [4-8].  However,  as  with  non-encapsulated  allo-
genic islets, the problem of islet tissue shortage still
exists. this is aggravated, because microcapsules are
floating freely in the peritoneal cavity without any vas-
cularisation.  therefore,  4  –  5  times  higher  islet  cell
masses are needed to guarantee normoglycemia com-
pared to non-encapsulated islets transplanted intrapor-
tally  [4].  a  reasonable  concept  to  overcome  these
shortcomings is the cryopreservation and subsequent
storage of microencapsulated allogenic islets, to allow
their unlimited collection and use on demand. In this
line of reasoning, recently we published a cryopreser-
vation protocol for encapsulated islets with promising
short-term transplantation data (4 weeks) [9]. Howev-
er, before a clinical application of these cryopreserved
immunoprotected transplants seems to be reasonable,
long-term  functionality  data  in  vivo  are  highly  war-
ranted.  therefore,  here  we  report  for  the  first  time
long-term transplantation outcome data for these cry-
opreserved encapsulated islet cells. 
MatERIaLs and MEtHods
Isolation of  rat islets
Pancreatic  islets  were  isolated  from  male  cd  rats
(charles River, sulzfeld, germany) with a body weight
of 250 – 270 g and 6 – 8 weeks of age, as described
previously [4, 9]. Briefly, the rats were anaesthetised by
intraperitoneal  pentobarbital  administration  (60
mg/kg). then a midline abdominal incision was per-
formed, the pancreas was exposed and injected via the
pancreatic  duct  with  Hank’s  balanced  salt  solution
(HBss;  Biochrom  Kg,  Berlin,  germany)  containing
0.5  mg/ml  collagenase  (serva  PanPlus,  Heidelberg,
germany). after sacrificing the animal, the pancreatic
tissue was surgically removed and incubated for 7 min
at 37ﾰc in the collagenase solution. Mechanical dis-
ruption of the digested pancreatic tissue was achieved
by further incubation in collagenase solution at 37ﾰc
for 7 min, interrupted every 80 seconds by shaking for
15  seconds.  digestion  was  stopped  by  addition  of
4ﾰc-cold  HBss  plus  10%  fetal  calf  serum  (fcs;
greiner Laboratories, frickenhausen, germany). Islet
purification was achieved using a discontinuous three-
phase  ficoll  density  gradient  (densities:  1.090,  1.077
and 1.040). Before encapsulation and cryopreservation
islets were cultured overnight in RPMI-1640 medium
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5%  co2.  the  medium  was  supplemented  with  5.1
mmol/l  glucose,  10%  fcs,  0.2  g/l  glutamax,  200
u/ml penicillin, 200 ﾵg/ml streptomycin (gibco BRL,
Paisley,  scotland,  gB)  and  50  ﾵg/ml  ciprofloxacin
(Bayer, Leverkusen, germany). 
Islet encapsulation
Microencapsulation was performed by using ultra-high
viscosity alginate of clinical grade [4]. Briefly, for mi-
crocapsule  formation  the  alginate  was  dissolved  in
sterile, endotoxin-free 0.9% physiologic saline solution
at a concentration of 0.7% (w/v). Human serum albu-
min (3% Hsa; Pharmacia, Erlangen, germany) was
added to the alginate solution before cross-linking. for
microcapsule formation a two-channel air jet droplet
generator was used. the islet containing microcapsules
were dropped into a 20 mM Bacl2 solution adjusted to
290  mosm  with  appropriate  amounts  of  nacl  and
buffered to pH 7 with 5 mM histidine. after 20 min,
the islet containing microcapsules were washed three
times with physiologic saline solution and then treated
with 6 mM na2so4 saline solution for 30 min at 37
ﾰc to precipitate excess Ba2+ ions. the microcapsules
obtained by this enﾬcapsulation procedure had a di-
ameter of approximately 700 – 800 ﾵm and contained
on average one islet, in rare cases two or three. 
Cryopreservation
Microencapsulated  cd  rat  islets  were  cryopreserved
with a protocol described previously [9]. Briefly, im-
mediately after encapsulation ∼500 microencapsulated
islets were transferred into a cryovial (2ml) and re-sus-
pended in 0.2 ml of RPMI plus 10% fcs. thereafter,
the  cryoprotectant  dimethyl  sulfoxide  (dMso  =
Me2so) was added in a stepwise manner, starting with
0.1 ml of 2.0 M dMso for 5 min at 0 ﾰc, followed by
0.1 ml of 2.0  M dMso for 5 min at 0ﾰc and finally
0.4 ml 3.1 M dMso for 5 min at 0ﾰc. When this pre-
freezing phase was finished the cryovials were trans-
ferred  into  the  chamber  of  a  computer-controlled
freezing machine (BV-8, consarctic, Heidelberg, ger-
many). When the freezing program had been complet-
ed the cryovials were transferred into liquid nitrogen.
after storage in liquid nitrogen for at least 7 days, cry-
ovials  with  frozen  islets  were  plunged  into  a  water
bath maintained at 37ﾰc and rapidly thawed to 0 ﾰc at
a  rate  of  approximately  200ﾰc/min.  thereafter,
dMso was removed from the islets by repeated addi-
tions of 0.75 M sucrose solution in a stepwise manner
(adding 0.17 ml every 5 min for a period of 30 min). 
Animals
Male Wistar rats (charles River, sulzfeld, germany) 6
– 8 weeks old, were used as recipients for microencap-
sulated  islets.  two  weeks  before  transplantation  rats
were rendered diabetic via intraperitoneal injections of
streptozotocin (60mg/kg body weight; sigma aldrich,
steinheim,  germany)  freshly  dissolved  in  citrate
buffer. only animals exhibiting blood sugar concentra-
tions greater than 350mg/dl in four consecutive mea-
surements were used as recipients. all animal studies
were  approved  by  the  Landesamt  f￼r  naturschutz
(Recklinghausen, germany, no. 50.10.32.08.037).
Transplantation of  islets
transplants  were  made  under  sterile  conditions.
cryostored microencapsulated rat islets were injected
into the peritoneal cavity by using a 20 gauge needle
(Vasofixﾮ, Braun, Melsungen, germany). Before treat-
ment the Wistar rats were anaesthetized by intraperi-
toneal pentobarbital administration (50 mg/kg). Each
rat (n = 14) received 2500 cryostored encapsulated rat
islets. control animals received the same number of
either  non-cryostored  non-encapsulated  (n  =  14)  or
non-cryostored  encapsulated  (n  =  14)  rat  islets,  re-
spectively.
Intraperitoneal glucose tolerance test (IPGTT)
after transplantation plasma glucose levels of islet re-
cipients were monitored biweekly. Blood samples were
taken from the tail vein under non-fasting conditions
(8 a.m.; standard laboratory chow ad libitum overnight)
and plasma glucose levels were determined by means
of the glucose-oxidase method with a clinical analyzer
(nova  Biomedical,  R￶dermark,  germany).  the  rats
were considered to be normoglycemic when the plas-
ma  glucose  levels  were  lower  than  200  mg/dl.  an
IPgtt was performed in fasting (12 hours), unanaes-
thetized  rats  transplanted  with  cryostored  or  control
(fresh, non-cryostored) microencapsulated rat islets 2,
12 and 56 weeks after transplantation, using a 5% glu-
cose solution (2g/kg body weight). Plasma glucose lev-
els were measured at 0, 30, 60 and 120 minutes. 
Microcapsule explantation
grafts  were  retrieved  from  animals  which  received
non-cryostored  encapsulated  rat  islets  (n  =  3  at  12
weeks and n = 3 at 56 weeks after transplantation) and
cryostored encapsulated rat islets (n = 3 at 12 weeks
and n = 3 at 56 weeks after transplantation). under
anaesthesia a 2-cm incision was made in the abdomen
and capsules were explanted by repeated flushes with
warmed 0.9% nacl solution. the abdomen was su-
tured and the animals checked daily for blood glucose
concentrations.
Assessment of  insulin secretion by a static incubation
assay
the static incubation assay was used to assess the in-
sulin secretion response of non-cryostored non-encap-
sulated  (control),  non-cryostored  encapsulated  (con-
trol) or cryostored encapsulated islets after a glucose
challenge  both  before  transplantation  and  after  re-
trieval of the capsules [9]. 10 samples of 10 cryostored
or control islets of equal size and shape were hand-
picked and transferred into a culture-insert (membrane
pore diameter 12 ﾵm; Millicell Pcf, Millipore, france).
the insert was put into a well of a 24-well culture-plate
(falcon Multiwell, Becton dickinson, usa). Basal in-
sulin secretion was measured after 1.5 hour incubation
at 37ﾰc in RPMI 1640 + d-glucose 1 g/l + 3% Hsa.
then the inserts with islets were transferred into hy-
perglycemic culture-media (RPMI 1640 + d-glucose 3
g/l + 3% Hsa) for further 1.5 hours. aliquots of the
media were stored at –20ﾰc after removal of the in-
serts.  Rat  insulin  was  measured  with  the  rat-insulin
ELIsa (Mercodia, uppsala, sweden). Results are given
in ng/islet/1.5h for rat islets.
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significance of differences was calculated with an un-
paired  student's  t-test  (two-sided).  all  calculations
have  been  performed  with  Kaleidagraph  4.0.3  for
Macintosh  computers  (synergy  software,  Reading,
Pa. usa).
REsuLts
Graft survival
Prior to transplantation, the insulin secretion capacity
of non-cryostored and cryostored encapsulated islets
cultured  for  one  day  was  determined.  as  shown  in
table  1,  non-cryostored  and  crystored  encapsulated
cd rat islets responded well to a high glucose stimu-
lus. the insulin increase upon a glucose challenge was
comparable to that of the corresponding non-encap-
sulated islets, even though the absolute amount of in-
sulin was lower, presumably due to diffusion restric-
tions  within  the  cross-linked  alginate  matrix.  trans-
plantation of 2500 non-encapsulated cd rat islets into
the peritoneal cavity of diabetic Wistar rats resulted in
normoglycemia  for  about  6  to  9  days.  In  contrast,
when  non-crystored  or  cryostored  encapsulated  rat
islets  were  transplanted  under  the  same  conditions
normoglycemia was achieved for more than 360 days
(table  2).  normoglycemic  blood  sugar  levels  were
generally reached within 24 h of transplantation. graft
explantation  from  animals  transplanted  with  non-
cryostored or cryostored encapsulated islets 12 and 56
weeks after transplantation resulted immediately in the
reappearance of hyperglycaemia associated with blood
glucose  concentrations  above  500  mg/dl.  taken  to-
gether,  transplantation  of  cryostored  as  well  as  of
non-crystored  encapsulated  islets  in  immunocompe-
tent rats enables stable graft function without the need
of immunosuppression. 
IPGTTs
figure 1 illustrates the blood glucose profiles of Wis-
tar rats transplanted with non- cryostrored and cryos-
tored microencapsulated cd rat islets during IPgtts
2, 12 and 56 weeks after transplantation. as indicated,
rats  transplanted  with  cryostored  encapsulated  rat
islets  showed  the  same  blood  glucose  concentration
after  overnight  fasting  (time  zero)  as  the  rats  trans-
planted with non-cryostored encapsulated islets (con-
trols). More importantly, the subsequent glucose clear-
ance kinetics up to 120 min were comparable. taken
together, transplantation of cryostored and non-cryos-
tored  encapsulated  islets  in  immunocompetent  rats
leads  to  normal  glucose  clearance  kinetics  up  to  56
weeks after transplantation. 
Retrieved microcapsules
consistent  with  the  results  of  the  IPgtts  the  re-
trieved encapsulated rat islets responded well to a glu-
cose challenge (table 1). 
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Table 1. Insulin secretion of non-cryopreserved non-encapsulated, non-cryopreserved encapsulated and cryopreserved encapsu-
lated rat islets in a static incubation assay before, 12 and 56 weeks after transplantation. 
Non-encapsulated Non-cryopreserved  Cryopreserved 
encapsulated encapsulated
Time Basal Stimulated Basal Stimulated Basal Stimulated
(ng/islet/1,5h) (ng/islet/1,5h) (ng/islet/1,5h) (ng/islet/1,5h) (ng/islet/1,5h) (ng/islet/1,5h)
before 2.9 ﾱ 1.0  22.1 ﾱ 5.5 2.1 ﾱ 0.3 15.8 ﾱ 4.6 2.0 ﾱ 0.6 16.5 ﾱ 4.0
*12 weeks -- 1.8 ﾱ 0.5  15.1 ﾱ 2.7  2.0 ﾱ 0.7  14.9 ﾱ 2.1 
*56 weeks -- 1.9 ﾱ 0.6  15.7 ﾱ 4.3 2.2 ﾱ 0.4  15.1 ﾱ 4.3
data are given as mean ﾱ sE; n = 3 independent experiments; *Measurements were performed after retrieval
Table 2. graft function of non-encapsulated non-cryopreserved, non-cryopreserved encapsulated and cryopreserved encapsu-
lated cd rat islets transplanted into the peritoneal cavity of diabetic Wistar rats.
Transplant Recipient Islet Donor Treatment Time of graft function (d)
Wistar rat cd Rat none 6.8 ﾱ 1.8
Wistar rat cd Rat Microcapsules 84!, 84!, 84!, 
392!, 392!, 392!,
90ﬁ, 150ﬁ, 166ﬁ, 242ﬁ, 412ﬁ, 
418ﬁ, 432ﬁ, 422ﬁ, 
Wistar rat  cd rat cryopreservation 84!, 84!, 84!, 
Microcapsules 392!, 392!, 392!,
156ﬁ, 169ﬁ, 175ﬁ, 278ﬁ, 413ﬁ, 
412ﬁ, 444ﬁ, 461ﬁ
! time of explantation, ﬁ ongoing graft function
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We report for the first time long-term graft survival
(>1  year)  of  cryopreserved  encapsulated  allogenic
pancreatic  islets  in  immunocompetent  diabetic  rats
without immunosuppression. 
as  has  recently  been  shown,  long-term  normo-
glycemia of type 1 diabetic patients can be achieved by
allogenic human islet transplantation [1, 2]. However,
this  technique  requires  the  administration  of  im-
munoﾬsupﾬpressiva that are well-known to be associ-
ated with serious side effects. a bioartificial pancreas
consisting  of  islets  immunoprotected  by  an  alginate
microcapsule provides an alternative approach to over-
come the rejection problem (10-12). In most of the
studies islets were entrapped in ca2+-cross-linked algi-
nate-polylysine-alginate  microcapsules  according  to
the protocol of Lim and sun (1980). unfortunately,
the results obtained by various groups using this mi-
crocapsule formulation in the last two decades were
very inconsistent. Most importantly, graft survival was
extremely random and was generally too limited for
therapeutic  applications  of  these  microcapsules  [13-
15]. the reasons for this are presumably the cytotoxic-
ity of the polyamino acid and the mechanical instabili-
ty of the microcapsules [16, 17]. Microcapsules made
of alginate cross-linked with Ba2+ do not share these
disadvantages [18]. duvivier-Kali et al. [7] have report-
ed that such microcapsules protect islets against allore-
jection and autoimmunity. furthermore, omer et al.
[8] found that Ba2+ cross-linked alginate microcapsules
protect  neonatal  pancreatic  cell  clusters  (nPcc’s)
when  transplanted  in  the  streptozotocin  diabetic
Balb/c mouse model for 20 weeks. We have recently
shown that use of highly purified and ultra high-vis-
cosity alginates when cross-linked internally and exter-
nally together with Ba2 resulted in microcapsules of
extremely high stability, particularly when proteins (e.g.
human  serum  albumin)  are  incorporated  simultane-
ously [19, 20, 21]. Moreover, we reported that islets
entrapped in these novel capsules enable survival and
function of adult rat and human islets in immunocom-
petent  mice  without  immunosuppression  for  >7
months  [4].  However,  when  dealing  with  allogenic
islets,  instead  of  xenogenic  material  (e.g.  porcine
islets), the shortage of islet tissue is a major problem.
a  reasonable  concept  to  overcome  these  shortcom-
ings is the cryopreservation and subsequent storage of
microencapsulated allogenic islets, to allow their un-
limited collection and use on demand. However, previ-
ous reports indicated that cryopreservation may lead
to substantial losses of viability and functionality of
non-encapsulated pancreatic islet cells [22, 24]. In con-
trast, we reported recently a novel and gently cryop-
reservation protocol for rat islets encapsulated in algi-
nate-based microcapsules [9]. Importantly, the cryop-
reserved  encapsulated  islets  showed  post  thawing  in
vitro  an  insulin  increase  upon  a  glucose  challenge
comparable to that of non-cryopreserved encapsulat-
ed islets. Moreover, a stable short-term graft (4 weeks)
function without the need of immunosuppression was
detected after transplantation of 2500 cryopreserved
encapsulated  cd  rat  islets  in  streptozotocin-diabetic
Wistar rats. However, to precisely assess the potential
of this technique and to carry on this approach to hu-
man islets, long-term functionality data are highly war-
ranted. therefore, in this study we have transplanted
2500 cryopreserved alginate encapsulated cd rat islets
in  diabetic  Wistar  rats  without  immunosuppressiva
and analysed the glucose profile of these animals for
over 1 year. By these means, we have demonstrated
that cryopreserved encapsulated islets maintained sta-
ble graft function for the whole duration of the study
(some of the experiments are still ongoing), implying
the long-term functionality of the graft, the absence
of  rejection  and  the  stability  of  the  microcapsules.
this claim was strengthens by the finding that the pat-
tern of glucose clearance during IPgtts differed not
from that of Wistar rats transplanted with non-cryop-
reserved encapsulated cd rat islets 2, 12 and 56 weeks
after transplantation. this was also confirmed by stud-
ies of insulin secretion of some transplants explanted
after 12 and 56 weeks. taken together, the presented
data demonstrate that cryopreserved encapsulated rat
islets can reverse diabetes for a long period of time
similarly to non-cryopreserved encapsulated rat islets
without the need for immunosuppressiva. this is very
promising because to our knowledge long-term graft
function of cryoprserved encapsulated islets has not
been reported in the literature. future studies will now
have to carry on this approach to human islets, aiming
to apply such a bioartifical pancreas consisting of cry-
opreserved encapsulated islets in humans. 
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